June 21, 2022
Recent prospective studies suggest that more than half of patients with Type 2 diabetes have concomitant NAFLD and more than one in three have NASH.
Other recent research tells us that patients with both diseases are at significantly increased risk of heart disease and cancer and are likely to have lower quality-of-life scores when compared to patients with T2D alone.
Join endocrinologist Kenneth Cusi, MD, forecaster/podcaster Roger Green, and their renowned guests to focus on the scale of the problem (HINT: large and scary!) and practical things you can do today to diagnose and treat these patients more effectively.
Fatty Liver Researcher and endocrinology key opinion leader Ken Cusi discusses the high levels of NAFLD prevalence and fibrosis among Type 2 Diabetes Mellitus patients and the value of early screening, particularly in endocrinology clinics, where the percent of patients with NAFLD and NASH fibrosis is double what we find in primary care.
Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.
Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.
This episode discusses the unique role NASH cirrhosis studies can play in clinical trial design, particularly in the transition from biopsy as gold standard to a post-biopsy world. Stephen Harrison starts this conversation by discussing why we focus on NASH cirrhosis and goes on to review the recent presentation of results from the REVERSE study on obeticholic acid. Jörn Schattenberg and Mazen Noureddin add their perspectives to the conversation.
Co-authors Michelle Long and Mazen Noureddin join Louise Campbell and Roger Green to discuss their recent publication on Best Practice in lean NASH. This conversation focuses on why early diagnosis is so important when dealing with Lean NASH.
Co-authors Michelle Long and Mazen Noureddin join Louise Campbell and Roger Green to discuss their recent publication on Best Practice in lean NASH. This conversation focuses on the elegant one-page diagnostic algorithm they recommend for diagnosing Lean NASH in “normal” BMI patients with signs of liver disease.
Co-authors Michelle Long and Mazen Noureddin join Louise Campbell and Roger Green to discuss their recent publication on Best Practice in lean NASH. This conversation focuses on how this article came to be and the key steps in researching and writing it.
Co-authors Michelle Long and Mazen Noureddin join Louise Campbell and Roger Green to discuss their recent Clinical Practice Update in Gastroenterology titled “Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.”
In this conversation from September 2021, Anthony Villiotti of NASH kNOWledge joins Louise Campbell and Roger Green to discuss his “biggest story of the summer:” two publications, on demonstrating that NASH prevalence and incidence may be far higher than we believe and another demonstrating how limited public knowledge about NASH is today.
Ian Rowe’s decision curve model does an excellent job of modeling the success rate and cost effectiveness of modeling early NASH diagnosis. However, as Louise Campbell points out, simply getting the patient diagnosed does not mean therapeutic success, which has implications for the early diagnosis model and broader patient management issues.
Hepatology Researcher and Key Opinion Leader Stephen Harrison discussed results of his 2021 publication in the Journal of Hepatology that